Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Danek Group

This article was originally published in The Gray Sheet

Executive Summary

Spinal implant firm's proposed business combination with French firm Sofamor to form Sofamor/Danek Group calls for Danek to issue 6.5 mil. shares of its common stock to shareholders of Sofamor, according to an exchange ratio based on Danek's recent share price. Danek announced the deal with Sofamor, which also makes spinal implants, in March ("The Gray Sheet" April 5, p. 11). In addition, Danek will pay $6.8 mil. in cash to a dissenting Sofamor stockholder; 399,240 additional Danek shares also will be issued "to acquire certain intellectual property rights under a related purchase agreement." Danek says the total shares to be issued "will represent approximately 28.3% of Sofamor/Danek Group's outstanding shares after the combination." Danek shareholders will vote on the transaction at the annual meeting in Memphis, Tennessee on June 21.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel